Back

Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study

29 August 2017 (08:51 - 09:01)
Organised by:
Congress Presentation Part of: Hot Line: Late-Breaking Clinical Trials 4 Diabetes, dysglycaemia and metabolic syndrome ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Hiroshi Itoh

Keio University School of Medicine, Tokyo (Japan)

12 More presentations in this session

Presentation thumbnail
Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial
Professor M. Landray (Oxford, GB)
Slides Video
Presentation thumbnail
Discussant review: Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial
Professor J. Chapman (Paris, FR)
Slides Video
Presentation thumbnail
Panel discussion.
Video
Presentation thumbnail
Discussant review: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study
Professor E. Prescott (Copenhagen, DK)
Slides Video
Presentation thumbnail
Panel discussion.
Video

Access the full session

Session thumbnail
Hot Line: Late-Breaking Clinical Trials 4

The Event

Event poster

ESC Congress 2017

29 August 2017 08:51 CET
You may be interested in
thumbnail
Congress Presentation
Statin therapy for primary prevention of microvascular complications in patients with heart failure and type 2 diabetes: a target trial emulation
28 August 2026
thumbnail
Congress Presentation
The current LDL-C target <1.4mmol/l of the ESC is achieved in less than 16% of patients with Coronary Heart Disease despite effective lipid-lowering therapy: Data from the LLT-R registry
28 August 2020
thumbnail
Webinar
Managing cardiovascular aspects in diabetes and metabolic syndrome patients
14 February 2022
thumbnail
Congress Presentation
The impact of statin treatment intensity after endovascular revascularization for lower extremity peripheral artery disease
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources